Financial reports
ARS
2023 FY
Annual report to shareholders
26 Apr 24
10-K
2023 FY
Annual report
1 Apr 24
10-Q
2023 Q3
Quarterly report
14 Nov 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
10-Q
2023 Q1
Quarterly report
10 May 23
10-K
2022 FY
Annual report
7 Mar 23
10-Q
2022 Q3
Quarterly report
14 Nov 22
10-Q
2022 Q2
Quarterly report
15 Aug 22
10-Q
2022 Q1
Quarterly report
16 May 22
10-K
2021 FY
Annual report
30 Mar 22
Current reports
8-K
Departure of Directors or Certain Officers
22 Feb 24
8-K
Other Events
20 Feb 24
8-K
Amendments to Articles of Incorporation or Bylaws
1 Feb 24
8-K
Other Events
29 Jan 24
8-K
Departure of Directors or Certain Officers
22 Jan 24
8-K
Departure of Directors or Certain Officers
2 Jan 24
8-K
Departure of Directors or Certain Officers
28 Dec 23
8-K
Departure of Directors or Certain Officers
22 Dec 23
8-K
Departure of Directors or Certain Officers
15 Nov 23
8-K
Alaunos Therapeutics Announces Third Quarter 2023 Financial Results, Phase 1 Clinical Data and Continued Exploration of Strategic Alternatives
14 Nov 23
Registration and prospectus
424B5
Prospectus supplement for primary offering
30 Nov 22
424B5
Prospectus supplement for primary offering
28 Nov 22
424B5
Prospectus supplement for primary offering
7 Sep 22
S-3/A
Shelf registration (amended)
31 Aug 22
S-3
Shelf registration
12 Aug 22
S-8
Registration of securities for employees
30 Mar 22
S-8
Registration of securities for employees
6 Aug 20
S-8
Registration of securities for employees
8 May 20
424B5
Prospectus supplement for primary offering
5 Feb 20
424B5
Prospectus supplement for primary offering
4 Feb 20
Proxies
DEFA14A
Additional proxy soliciting materials
26 Apr 24
DEF 14A
Definitive proxy
26 Apr 24
PRE 14A
Preliminary proxy
15 Apr 24
DEFA14A
Additional proxy soliciting materials
25 Apr 23
DEF 14A
Definitive proxy
25 Apr 23
PRE 14A
Preliminary proxy
14 Apr 23
DEFA14A
Additional proxy soliciting materials
27 Apr 22
DEF 14A
Definitive proxy
27 Apr 22
PRE 14A
Preliminary proxy
15 Apr 22
DEFA14A
Additional proxy soliciting materials
7 Apr 21
Other
EFFECT
Notice of effectiveness
8 Sep 22
CORRESP
Correspondence with SEC
2 Sep 22
UPLOAD
Letter from SEC
19 Aug 22
SEC STAFF
SEC staff action: Order
11 Mar 21
SEC STAFF
SEC staff action: Order
10 Feb 21
UPLOAD
Letter from SEC
28 Oct 20
CORRESP
Correspondence with SEC
27 Oct 20
UPLOAD
Letter from SEC
27 Oct 20
UPLOAD
Letter from SEC
22 Oct 20
EFFECT
Notice of effectiveness
22 Feb 19
Ownership
SC 13G/A
DISCOVERY CAPITAL MANAGEMENT, LLC / CT
14 Feb 24
SC 13G/A
MSD Partners, L.P.
13 Feb 24
4
Dale Curtis Jr. Hogue
23 Jan 24
4
Dale Curtis Jr. Hogue
3 Jan 24
3
Dale Curtis Jr. Hogue
3 Jan 24
4
Kevin S. Sr. Boyle
5 Sep 23
144
Notice of proposed sale of securities
1 Sep 23
4
Robert W Postma
8 Jun 23
4
Robert Hofmeister
8 Jun 23
4
Mary Thistle
8 Jun 23